Abbott Laboratories (ABT) Income Statement Flow — TTM through Q2 2026
Calculated from the four most recent reported quarters, ending (reported ).
Abbott Laboratories (ABT) Revenue by Product Segment — TTM through Q2 2026
Aggregated from the four quarterly disclosures behind this TTM. Minor differences vs the company's annual filing can occur if reported segments changed mid-year.
| Segment | Revenue (USD) | % of total |
|---|---|---|
| Medical Devices | $19.1B | 40.9% |
| Diagnostic Products | $15.6B | 33.5% |
| Nutritional Products | $6.99B | 15% |
| Established Pharma | $4.93B | 10.6% |
| Total | $46.6B | 100% |
- Medical Devices$19.1B
- Diagnostic Products$15.6B
- Nutritional Products$6.99B
- Established Pharma$4.93B
- Total$46.6B
Abbott Laboratories (ABT) Revenue by Geography — TTM through Q2 2026
Aggregated from the four quarterly disclosures behind this TTM. Minor differences vs the company's annual filing can occur if reported regions changed mid-year.
| Region | Revenue (USD) | % of total |
|---|---|---|
| Non-US | $21.3B | 54% |
| UNITED STATES | $18.2B | 46% |
| Total | $39.5B | 100% |
- Non-US
- UNITED STATES
- Total
Revenue Breakdown — TTM through Q2 2026
In TTM through Q2 2026, Abbott Laboratories (ABT) reports revenue across 4 reportable product segments; the largest segment was Medical Devices at 40.9%, followed by Diagnostic Products (33.5%) and Nutritional Products (15%). Geographically, Non-US accounted for 54% of revenue, followed by UNITED STATES (46%).
Frequently asked questions
Data & methodology
Abbott Laboratories (ABT) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
- Buybacks1.16% TTM
- Dividend Profile2.30% yield
- Dividend Calculator
- Dividend Forecast
- Dividend Capture
- Stock Split History9 splits
How this company returns cash to shareholders — buybacks, dividends, and stock splits.